Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Zevra Therapeutics Inc (NASDAQ: ZVRA) closed the day trading at $7.26 up 0.69% from the previous closing price of $7.21. In other words, the price has increased by $0.69 from its previous closing price. On the day, 0.53 million shares were traded. ZVRA stock price reached its highest trading level at $7.45 during the session, while it also had its lowest trading level at $7.1.
Ratios:
For a better understanding of ZVRA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.00. In the meantime, Its Debt-to-Equity ratio is 1.83 whereas as Long-Term Debt/Eq ratio is at 1.81.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on April 02, 2024, Reiterated its Buy rating but revised its target price to $18 from $12 previously.
On March 17, 2023, Maxim Group started tracking the stock assigning a Buy rating and target price of $12.Maxim Group initiated its Buy rating on March 17, 2023, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 17 ’24 when Clifton R. LaDuane bought 2,000 shares for $6.77 per share. The transaction valued at 13,540 led to the insider holds 18,469 shares of the business.
Anderson Thomas bought 10,000 shares of ZVRA for $68,065 on Jul 16 ’24. The Director now owns 20,000 shares after completing the transaction at $6.81 per share. On Jul 12 ’24, another insider, Bode John B, who serves as the Director of the company, bought 10,000 shares for $5.87 each. As a result, the insider paid 58,661 and bolstered with 30,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZVRA now has a Market Capitalization of 382005248 and an Enterprise Value of 392215136. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.92 while its Price-to-Book (P/B) ratio in mrq is 9.39. Its current Enterprise Value per Revenue stands at 16.557 whereas that against EBITDA is -5.537.
Stock Price History:
Over the past 52 weeks, ZVRA has reached a high of $8.44, while it has fallen to a 52-week low of $3.89. The 50-Day Moving Average of the stock is 20.59%, while the 200-Day Moving Average is calculated to be 31.78%.
Shares Statistics:
Over the past 3-months, ZVRA traded about 723.58K shares per day on average, while over the past 10 days, ZVRA traded about 670390 shares per day. A total of 52.62M shares are outstanding, with a floating share count of 52.20M. Insiders hold about 0.79% of the company’s shares, while institutions hold 30.55% stake in the company. Shares short for ZVRA as of 1723680000 were 3824709 with a Short Ratio of 5.29, compared to 1721001600 on 3169614. Therefore, it implies a Short% of Shares Outstanding of 3824709 and a Short% of Float of 7.290000000000001.
